Biodesix (BDSX) Scheduled to Post Earnings on Friday

Biodesix (NASDAQ:BDSX - Get Free Report) will be releasing its earnings data before the market opens on Friday, November 1st. Analysts expect Biodesix to post earnings of ($0.08) per share for the quarter. Biodesix has set its FY 2024 guidance at EPS.Parties that are interested in participating in the company's conference call can do so using this link.

Biodesix (NASDAQ:BDSX - Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.01. The firm had revenue of $17.93 million during the quarter, compared to analysts' expectations of $16.05 million. Biodesix had a negative return on equity of 505.95% and a negative net margin of 73.08%. During the same period last year, the business earned ($0.17) earnings per share. On average, analysts expect Biodesix to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Biodesix Stock Performance

Biodesix stock traded up $0.01 on Friday, hitting $1.64. The company's stock had a trading volume of 51,839 shares, compared to its average volume of 149,190. Biodesix has a one year low of $1.15 and a one year high of $2.21. The firm has a market cap of $188.09 million, a P/E ratio of -2.98 and a beta of 1.22. The company has a quick ratio of 3.28, a current ratio of 3.28 and a debt-to-equity ratio of 0.99. The company has a fifty day moving average price of $1.74 and a 200-day moving average price of $1.59.

Wall Street Analyst Weigh In

BDSX has been the subject of several recent research reports. Craig Hallum assumed coverage on shares of Biodesix in a research report on Friday, July 26th. They issued a "buy" rating and a $3.00 price target for the company. Scotiabank started coverage on Biodesix in a report on Monday, September 16th. They issued a "sector outperform" rating and a $3.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $3.06.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.